JOUNCE THERAPEUTICS INC's ticker is JNCE and the CUSIP is 481116101. A total of 114 filers reported holding JOUNCE THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 0.78 and the average weighting 0.9%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2022 | $56,000 | -62.7% | 18,376 | +2.6% | 0.01% | -64.7% |
Q4 2021 | $150,000 | -1.3% | 17,913 | +20.8% | 0.02% | 0.0% |
Q1 2021 | $152,000 | -34.2% | 14,827 | -58.3% | 0.02% | -46.9% |
Q3 2018 | $231,000 | -26.2% | 35,529 | +153.1% | 0.03% | -31.9% |
Q1 2018 | $313,000 | – | 14,038 | – | 0.05% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
TRV GP II, LLC | 1,347,829 | $9,152,000 | 93.42% |
Ally Bridge Group (NY) LLC | 550,000 | $3,735,000 | 2.77% |
ACUTA CAPITAL PARTNERS, LLC | 813,500 | $5,524,000 | 2.58% |
TRV GP III, LLC | 1,148,780 | $7,800,000 | 2.12% |
Deep Track Capital, LP | 4,259,653 | $28,923,000 | 1.86% |
Logos Global Management LP | 1,400,000 | $9,506,000 | 1.23% |
PFM Health Sciences, LP | 3,972,868 | $26,976,000 | 1.01% |
Sofinnova Investments, Inc. | 1,481,219 | $10,057,000 | 0.76% |
SILVERARC CAPITAL MANAGEMENT, LLC | 248,347 | $1,686,000 | 0.70% |
RTW INVESTMENTS, LP | 4,680,412 | $31,780,000 | 0.66% |